Delving into the Latest Updates on Articaine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Articaine, Articaine hydrochloride (JAN/USP), 40-045

+ [7]

Target

SCNA

Action

blockers, modulators

Mechanism

SCNA blockers(Sodium voltage-gated channel alpha subunits blockers), Central nervous system modulators

Therapeutic Areas

Other Diseases

Active Indication

Anesthesia

Inactive Indication-

Originator Organization

North American Genomics LLC

Active Organization-

Inactive Organization

American Genomics, LLC

Thea Pharma Inc.

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (15 Aug 2025),

Anesthesia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC13H21ClN2O3S

InChIKeyGDWDBGSWGNEMGJ-UHFFFAOYSA-N

CAS Registry23964-57-0

This study will evaluate whether pre-emptive local anesthesia reduces sevoflurane consumption during pediatric day-case dental treatment performed under general anesthesia.
Children aged 4 to 12 years scheduled for elective dental treatment under general anesthesia will be included. Participants will be assigned to either receive pre-emptive local anesthesia before the dental procedure or receive no pre-emptive local anesthesia. General anesthesia will be standardized using sevoflurane, low fresh gas flow, endotracheal intubation, and bispectral index monitoring.
The main outcome will be sevoflurane consumption expressed as mL/kg/hour. Secondary outcomes will include anesthetic agent uptake, time from sevoflurane discontinuation to extubation, and estimated carbon dioxide-equivalent emissions.
The aim is to determine whether pre-emptive local anesthesia can reduce volatile anesthetic requirement and improve early recovery while maintaining adequate anesthetic depth in children undergoing dental general anesthesia.

Start Date01 Aug 2026

Sponsor / Collaborator

Erciyes Üniversitesi

CTRI/2025/10/095680

/ Not yet recruitingNot ApplicableIIT

Postoperative recovery with low-level laser therapy in reversing the anesthetic effect of 4 percent articaine: a randomized clinical trial - Dr.

Start Date02 Mar 2026

Sponsor / Collaborator-

ChiCTR2600122873

/ RecruitingNot ApplicableIIT

Observation of the Analgesic Effect of Celecoxib Combined with STA Painless Anesthesia Device in the Perioperative Period of Guided Bone Regeneration Surgery

Start Date27 Jan 2026

Sponsor / Collaborator-

100 Clinical Results associated with Articaine Hydrochloride

Login to view more data

100 Translational Medicine associated with Articaine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Articaine Hydrochloride

Login to view more data

844

Literatures (Medical) associated with Articaine Hydrochloride

01 Jul 2026·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Regional anesthesia in the emergency department: A review of key pharmacotherapeutic considerations

Review

Author: Gottlieb, Michael ; Riscinti, Matthew ; Rech, Megan A ; Ray, Lance ; Long, Brit

INTRODUCTION:

Opioid-associated risks and the opioid epidemic have accelerated interest in multimodal analgesia in the emergency department (ED). Regional anesthesia offers a targeted approach with reduced risk of systemic adverse effects and is increasingly used under ultrasound guidance.

OBJECTIVE:

This concise, evidence-based review explores pharmacological principles of local anesthetics describing key aspects of structure-activity relationship, providing context for agent selection. Additional considerations include dosing strategy, adjunctive medications, potential risks, toxicity mitigation, and operationalization of regional anesthesia in the ED.

DISCUSSION:

Regional anesthesia is used with increased frequency in the ED. Pharmacologic properties of commonly used local anesthetics and adjunctive agents determine their advantages and limitations as well as place in therapy. There are a variety of anesthetic agents, including amides (e.g., lidocaine, bupivacaine, ropivacaine, levobupivacaine) and esters (e.g., articaine, chloroprocaine) with differences in onset, duration, and toxicity profiles that influence agent selection in ED patient populations. Adjuncts such as epinephrine, dexamethasone, and alpha-2 agonists may extend nerve block duration or improve analgesia but introduce safety and operational considerations. Recognition of local anesthetic systemic toxicity (LAST) remains central to safe practice, underscoring the importance of weight-based dosing, ultrasound guidance, monitoring, and immediate access to lipid emulsion therapy. Systems-based approaches such as order sets, pharmacist involvement, and structured training support consistent and safe application of regional anesthesia in the ED setting.

CONCLUSIONS:

Safe integration of regional anesthesia in the ED requires pharmacologic literacy, standardized systems, and multidisciplinary support to optimize analgesia while minimizing risk.

01 May 2026·JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Articaine in oral and maxillofacial anesthesia: What does high-level evidence reveal about nerve block and infiltration strategies?

Review

Author: Batista da Silva Candido, Camila ; Özcan, Mutlu ; Groppo, Francisco ; Dascanio, Rafael

BACKGROUND:

Local anesthesia is a cornerstone of office-based oral and maxillofacial surgical practice, but achieving predictable anesthesia in mandibular procedures remains a persistent clinical challenge.

PURPOSE:

This umbrella review aimed to synthesize high-level evidence on the efficacy, safety, and clinical performance of 4% articaine in oral and maxillofacial anesthesia, with emphasis on nerve block and infiltration strategies.

STUDY DESIGN:

An umbrella review of systematic reviews and meta-analyses was conducted following Preferred Reporting Items for Overviews of Reviews guidelines.

METHODS:

Electronic searches were performed in PubMed/MEDLINE, Scopus, Web of Science, and Embase. The Population Intervention Comparison Outcomes framework included patients undergoing oral and maxillofacial surgical procedures; the intervention was 4% articaine; comparators were other local anesthetics; and outcomes included anesthetic success, latency, duration, need for supplemental anesthesia, and adverse events. Twenty-five systematic reviews were included, encompassing 228 primary studies. Methodological quality was assessed using AMSTAR-2, and overlap was quantified using the corrected covered area (3.18%).

RESULTS:

A total of 171 records were identified, of which 25 reviews (14.6%) were included. Articaine did not demonstrate consistent superiority over lidocaine or mepivacaine for inferior alveolar nerve block, particularly in inflammatory conditions. However, articaine significantly improved anesthetic success when used as supplemental buccal infiltration following block failure and as primary infiltration in posterior mandibular regions, reducing the need for reinjection. In surgical procedures, including third molar extraction, articaine demonstrated faster onset and comparable duration. Adverse event rates were similar across anesthetics, with no evidence of increased risk of persistent paresthesia.

CONCLUSIONS:

Articaine is not intrinsically superior for mandibular nerve blocks but provides clinically meaningful advantages when used in infiltration-based strategies. These findings indicate that anesthetic success is primarily determined by technique optimization rather than anesthetic selection alone.

01 Apr 2026·Journal of Pharmacy and Bioallied Sciences

Efficacy of Different Local Anesthetics for Pain Management in Surgical Removal of Palatally Placed Impacted Maxillary Canines: A Comparative Study

Article

Author: Alqahtani, Ali Fahed ; Kilari, Dharani Chowdary ; Tiwari, Rahul ; Malhotra, Aayush ; Ahmed, Tanveer ; Kota, Mohammad Zahir ; Das, Nirman ; Prashant, M. C.

Objective::

To compare the efficacy of different local anesthetics in managing pain during the surgical removal of palatally placed impacted maxillary canines.

Materials and Methods::

A randomized controlled study was conducted on 90 patients requiring surgical removal of palatally impacted maxillary canines. Patients were divided into three groups, each receiving a different local anesthetic: 2% lidocaine with epinephrine (Group A), 4% articaine with epinephrine (Group B), and 0.5% bupivacaine with epinephrine (Group C). Pain levels were assessed intraoperatively and postoperatively using the Visual Analog Scale (VAS).

Results::

Articaine demonstrated superior intraoperative pain control compared to lidocaine and bupivacaine (VAS score: 1.5 ± 0.6 vs. 3.2 ± 0.8 and 2.8 ± 0.7, respectively, P < 0.05). Postoperative pain relief was significantly prolonged in the bupivacaine group (VAS score at 6 hours: 2.1 ± 0.9 vs. 4.5 ± 1.0 for lidocaine and 3.8 ± 0.9 for articaine, P < 0.05). No severe adverse effects were reported in any group.

Conclusion::

Articaine provides superior intraoperative pain control, while bupivacaine offers longer-lasting postoperative analgesia. The choice of anesthetic should depend on the clinical requirements of intraoperative versus postoperative pain management.

1

News (Medical) associated with Articaine Hydrochloride

02 Jan 2026

·www.einpresswire.com

July - September 2025 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

ADZYNMA (ADAMTS13, recombinant-krhn) Neutralizing antibodies with fatal outcome FDA is evaluating the need for regulatory action. FDA Safety Communication was issued on November 21, 2025: FDA Investigating Death Due to Neutralizing Antibodies to ADAMTS13 following Adzynma Treatment of Congenital Thrombotic Thrombocytopenic Purpura Asceniv (immune globulin intravenous, human-slra) Increased hypersensitivity reactions in patients receiving certain product lot FDA is evaluating the need for regulatory action. FDA Safety Communication was issued on October 28, 2025: Immune Globulin Intravenous (IGIV) and/or Immune Globulin Subcutaneous (IGSC) Lots with Increased Reports of Allergic/Hypersensitivity Reactions Benlysta (belimumab) injection Severe cutaneous adverse reactions FDA is evaluating the need for regulatory action. Braftovi (encorafenib) capsules Tafinlar (dabrafenib) capsules; tablets Zelboraf (vemurafenib) tablet Sarcoidosis FDA is evaluating the need for regulatory action. Cabometyx (cabozantinib) tablets Cometriq (cabozantinib) capsules Lenvima (lenvatinib) capsules Thrombotic microangiopathy FDA is evaluating the need for regulatory action. Cotellic (cobimetinib) tablets Mekinist (trametinib) tablets; oral solution Mektovi (binimetinib) tablets Sarcoidosis FDA is evaluating the need for regulatory action. ELEVIDYS (delandistrogene moxeparvovec-rokl) Mesenteric vein thrombosis following product-related acute liver injury The "Warnings and Precautions" and "Adverse Reactions - Postmarketing Experience" sections of the labeling for Elevidys were updated in November 2025 to include life-threatening mesenteric vein thrombosis. FDA Safety Communication was issued on November 14, 2025: FDA Takes Action on New Boxed Warning for Acute Serious Liver Injury and Acute Liver Failure Following Treatment with Elevidys and Revised Indication that is Limited to Ambulatory Duchenne Muscular Dystrophy Patients Firmagon (degarelix for injection) Myfembree (relugolix, estradiol, and norethindrone acetate) tablets Orgovyx (relugolix) tablets Drug interaction FDA is evaluating the need for regulatory action. Ifex (ifosfamide) injection Pregnancy, puerperium and perinatal conditions FDA is evaluating the need for regulatory action. Ogsiveo (nirogacestat) tablets Visual impairment FDA is evaluating the need for regulatory action. Orgovyx (relugolix) tablets Hypertension FDA is evaluating the need for regulatory action. Rezzayo (rezafungin for injection) Hypersensitivity The "Warnings and Precautions", "Adverse Reactions" and "Patient Counseling Information" sections of the labeling were updated in December 2025 to include information about hypersensitivity reactions, including anaphylaxis. Rezzayo labeling Septocaine (articaine hydrochloride and epinephrine injection) Mepivacaine hydrochloride injection (a particular generic product) Wrong drug administered FDA is evaluating the need for regulatory action. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug ApprovalBiosimilar

100 Deals associated with Articaine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02991	Articaine Hydrochloride	N01BB08	DB09009

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	United States	Thea Pharma Inc.	15 Aug 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05443009 (Pubmed \| J Am Dent Assoc)	Phase 3	Pain	76	4% articaine	drjfqudjhv(viwupgbfyw) = iyuhpaawza zgscwwohwj (fltnpyqqwm, 3.41)	Negative	01 Nov 2025
				2% lidocaine (buccal and palatal infiltration)	drjfqudjhv(viwupgbfyw) = usuqcsksid zgscwwohwj (fltnpyqqwm, 2.71)
FDA_CDER Manual	Phase 1	-	240	ARTICAINE	tuvnupucwx(imhnrmyucb) = The treatment effect (difference from placebo) was 65% in both studies. kyewamtqal (gqtolyusin )	Positive	15 Aug 2025
				placebo
NCT06047366 (CTgov)	Phase 4	Pulpitis	40	Articaine w/ epi+Mepivacaine plain+Sodium bicarbonate+Lidocaine w/ epi (Buffered)	nknjedkivg(urjtvornxj) = tdxfwrwwxp rirnlrghep (asvbtaiigv, stomtztvch - mmaobufhsy) View more	-	13 May 2025
				Articaine w/ epi+Mepivacaine plain+Lidocaine w/ epi (Unbuffered)	nknjedkivg(urjtvornxj) = edonvkirqi rirnlrghep (asvbtaiigv, ocwghkkuji - jdvqdehpxh) View more
NCT04829344 (CTgov)	Phase 3	Anesthesia	120	AG-920 (AG-920)	uuwddtwfid(fvjjdtyoeg) = ylsmwsqbkh wmrvfnjxsa (wjhxpmebta, 0.61) View more	-	10 Oct 2024
				Placebo (Placebo)	uuwddtwfid(fvjjdtyoeg) = ztmdapjfre wmrvfnjxsa (wjhxpmebta, 1.67) View more
NCT05501860 (CTgov)	Phase 3	Anesthesia	249	AG-920 (AG-920)	wuzgavjwth = wldwnrduoe pmmlnsjstw (nmpsxcnvit, shpihwqvtz - hbrwmiuuhd) View more	-	09 Oct 2024
				Placebo (Placebo)	wuzgavjwth = trnayyqazp pmmlnsjstw (nmpsxcnvit, lquuzljnxo - zsccqgibfd) View more
NCT05325853 (Phase 3, CTgov)	Phase 3	Anesthesia	61	AG-920 (AG-920)	vgtorwjzlu = lvzthexbez rxwjkmudlf (yxhgbqddwx, otgenuupnp - pjaqpybgdz) View more	-	25 Oct 2023
				Proparacaine Ophthalmic (Proparacaine)	vgtorwjzlu = nsdapalbjw rxwjkmudlf (yxhgbqddwx, hgpqyzlmdm - jjamchoiwf) View more
NCT04513652 (CTgov)	Phase 3	Anesthesia	120	AG-920 (AG-920)	tdohaggmbe = scaavxzcbc qlcdkwixxq (jyfzpyebkp, fhphjeefzb - alywzidoor) View more	-	28 Sep 2022
				Placebo (Placebo)	tdohaggmbe = balnksclpb qlcdkwixxq (jyfzpyebkp, sfonhhgayx - ormntfmpgo) View more
Phase 3 (ARVO2022)	Phase 3	-	120	AG-920	mxhmxrlidr(jezcplggxj) = 9% vs 10% ksofgypplb (lxnqseejzr ) View more	Positive	01 May 2022
				Placebo
NCT01862614 (Buffered Articaine, CTgov)	Phase 4	Anesthesia	80	articaine (Articaine)	cqgsrfvcti = cxtrtwawqb efiaudijmh (zeksevnzrg, jyilykvvxr - hckvtstdio) View more	-	02 Dec 2020
				articaine (Buffered Articaine)	cqgsrfvcti = xgnlikiwyb efiaudijmh (zeksevnzrg, ymrgxwlfbd - gqudyzwmcy) View more
NCT02457325 (CTgov)	Phase 4	Blood Loss, Surgical \| Drug-Related Side Effects and Adverse Reactions	50	articaíne (Surgery With 2%Articaine)	gsejbpqdzl(uauprzemsj) = ubinwbedhg blkstqbjlz (xmsuhlfkrs, 0.6) View more	-	24 Nov 2020
				articaíne (Surgery With 4%Articaine)	gsejbpqdzl(uauprzemsj) = kspxbjzwmc blkstqbjlz (xmsuhlfkrs, 0.6) View more